NAMS (NewAmsterdam Pharma Co NV) Cash-to-Debt : 835.43 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NewAmsterdam Pharma Co NV's cash to debt ratio for the quarter that ended in Sep. 2024 was 835.43.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NewAmsterdam Pharma Co NV could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's Cash-to-Debt or its related term are showing as below:

NAMS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68 Med: 835.43 Max: 11189.47
Current: 835.43

During the past 4 years, NewAmsterdam Pharma Co NV's highest Cash to Debt Ratio was 11189.47. The lowest was 0.68. And the median was 835.43.

NAMS's Cash-to-Debt is ranked better than
86.82% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs NAMS: 835.43

NewAmsterdam Pharma Co NV Cash-to-Debt Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NewAmsterdam Pharma Co NV Cash-to-Debt Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.68

323.18

3,712.13

5,674.17

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial							N/A	5,674.17	11,189.47	766.38	835.43

Competitive Comparison of NewAmsterdam Pharma Co NV's Cash-to-Debt

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Cash-to-Debt falls into.

NewAmsterdam Pharma Co NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NewAmsterdam Pharma Co NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	340.45	/	(0.06	+	0)
	=	5,674.17

NewAmsterdam Pharma Co NV's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	422.729	/	(0.24	+	0.266)
	=	835.43

NewAmsterdam Pharma Co NV (NAS:NAMS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NewAmsterdam Pharma Co NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.